| Patient Education |
|
Click here for patient education.
|
|
You are in: eMedicine Specialties >
Cardiology > Valvular Heart Disease
Tricuspid Stenosis
Article Last Updated: Jul 29, 2008
AUTHOR AND EDITOR INFORMATION
Section 1 of 12  
Author: Mary C Mancini, MD, PhD, Professor, Department of Surgery, Louisiana State University Health Sciences Center
Mary C Mancini is a member of the following medical societies: American Heart Association, American Medical Association, American Thoracic Society, Association for Academic Surgery, Association for Surgical Education, International College of Surgeons, International Society for Heart and Lung Transplantation, New York Academy of Sciences, Phi Beta Kappa, and Southern Thoracic Surgical Association
Editors: Park W Willis IV, MD, Sarah Graham Distinguished Professor of Medicine and Pediatrics, University of North Carolina at Chapel Hill School of Medicine; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Ronald J Oudiz, MD, Director of Pulmonary Hypertension, Associate Professor, Department of Medicine, Division of Cardiology, Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA; Amer Suleman, MD, Consultant in Electrophysiology and Cardiovascular Medicine, Department of Internal Medicine, Division of Cardiology, Medical City Dallas Hospital; Richard A Lange, MD, E Cowles Andrus Professor of Cardiology, Professor of Medicine, Johns Hopkins University School of Medicine
Author and Editor Disclosure
Synonyms and related keywords:
tricuspid stenosis, tricuspid valve, rheumatic heart disease, mitral stenosis, carcinoid, Ebstein anomaly, tricuspid valve dysfunction, myocardium aberrations, stenotic tricuspid valves, rheumatic fever, carcinoid syndrome, endocarditis, endomyocardial fibrosis, lupus, congenital tricuspid atresia, rheumatic fever, congenital tricuspid stenosis, atrial fibrillation, peripheral edema, ascites, congenital abnormalities, metabolic abnormalities, enzymatic abnormalities, active infective endocarditis, rheumatic tricuspid stenosis, carcinoid heart disease, infective endocarditis, Fabry disease, giant blood cysts, supravalvular obstruction from congenital diaphragms, intracardiac tumor, extracardiac tumor, thrombosis, emboli, large endocarditis vegetations
Background
Tricuspid valve dysfunction can result from morphological alterations in the valve or from functional aberrations of the myocardium. Tricuspid stenosis is almost always rheumatic in origin and is generally accompanied by mitral and aortic valve involvement.1 Most stenotic tricuspid valves are associated with clinical evidence of regurgitation that can be documented by performing a physical examination (murmur), echocardiography, or angiography. Stenotic tricuspid valves are always anatomically abnormal, and the cause is limited to a few conditions. With the exceptions of congenital causes or active infective endocarditis, tricuspid stenosis takes years to develop.2, 3
Pathophysiology
Tricuspid stenosis results from alterations in the structure of the tricuspid valve that precipitate inadequate excursion of the valve leaflets. The most common etiology is rheumatic fever, and tricuspid valve involvement occurs universally with mitral and aortic valve involvement. With rheumatic tricuspid stenosis, the valve leaflets become thickened and sclerotic as the chordae tendineae become shortened. The restricted valve opening hampers blood flow into the right ventricle and, subsequently, to the pulmonary vasculature. Right atrial enlargement is observed as a consequence. The obstructed venous return results in hepatic enlargement, decreased pulmonary blood flow, and peripheral edema. Other rare causes of tricuspid stenosis include carcinoid syndrome, endocarditis, endomyocardial fibrosis, systemic lupus erythematosus, and congenital tricuspid atresia.4, 2, 3 In the rare instances of congenital tricuspid stenosis, the valve leaflets may manifest various forms of deformity, which can include deformed leaflets, deformed chordae, and displacement of the entire valve apparatus. Other cardiac anomalies are usually present.1
Frequency
United States
Tricuspid stenosis is rare, occurring in less than 1% of the population. While found in approximately 15% of patients with rheumatic heart disease at autopsy, it is estimated to be clinically significant in only 5% of these patients. The incidence of the congenital form of the disease is less than 1%.
International
Tricuspid stenosis is found in approximately 3% of the international population. It is more prevalent in areas with a high incidence of rheumatic fever. The congenital form of the disease is rare and true incidence is not available.
Mortality/Morbidity
The mortality associated with tricuspid stenosis depends on the precipitating cause. The general mortality rate is approximately 5%.
Race
No racial predisposition is apparent.
Sex
Tricuspid stenosis is observed more commonly in women than in men, similar to mitral stenosis of rheumatic origin. The congenital form of the disease has a slightly higher male predominance.
Age
Tricuspid stenosis can present as a congenital lesion or later in life when it is due to some other condition. The congenital form accounts for approximately 0.3% of all congenital heart disease cases. The frequency of tricuspid stenosis in the older population, due to secondary causes, ranges from 0.3-3.2%.
History
- Fatigue, due to limited cardiac output, may be present.
- Systemic venous congestion leads to abdominal discomfort and swelling. The onset is usually gradual, but it may be rapid if atrial fibrillation or flutter develops. (For related information, see Medscape's Atrial Fibrillation Resource Center).
- Dyspnea may be present but is not severe unless concomitant mitral valve disease is present.
- Patients may complain about prominent pulsations in the neck.
- When tricuspid stenosis occurs concomitantly with mitral stenosis, the decrement of cardiac output to the pulmonary bed may paradoxically diminish the dyspnea, hemoptysis, and orthopnea typically seen with mitral stenosis.
- Obtain information regarding preceding rheumatic fever, symptoms of the carcinoid syndrome, and possible congenital abnormalities.
Physical
- With sinus rhythm (more common with tricuspid stenosis than with mitral stenosis), the jugular venous pulse increases and the A wave is prominent (may be confused with an arterial pulse).
- If atrial fibrillation occurs, the A wave is lost.
- Peripheral edema and ascites are frequent.
- Without significant mitral pathology, the patient should not be dyspneic and can probably lie flat without symptoms.
- A prominent right atrium may be palpable to the right of the sternum. If not obscured by mitral stenosis sounds, a tricuspid opening snap may be heard. A diastolic murmur is audible along the left sternal border or at the xiphoid, which increases with inspiration. Often, tricuspid regurgitation is also present, represented by a holosystolic murmur in a similar location.
- The first heart sound may be split widely. The second heart sound may be single. This single sound is due to the inaudible closure of the pulmonary valve from the decrease in blood flow through the stenotic tricuspid valve.
Causes
At least 4 conditions can cause obstruction of the native tricuspid valve. These include (1) rheumatic heart disease, (2) congenital abnormalities, (3) metabolic or enzymatic abnormalities, and (4) active infective endocarditis.
- Rheumatic tricuspid stenosis: In this entity, diffuse thickening of the leaflets occurs, with or without fusion of the commissures. The chordae tendineae may be thickened and shortened. Calcification of the valve rarely occurs. The leaflet tissue is composed of dense collagen and elastic fibers that produce a major distortion of the normal leaflet layers.
- Carcinoid heart disease: Carcinoid valve lesions characteristically manifest as fibrous white plaques located on the valvular and mural endocardium. The valve leaflets are thickened, rigid, and reduced in area. Fibrous tissue proliferation is present on the atrial and ventricular surfaces of the valve structure.
- Congenital tricuspid stenosis: These lesions are observed more commonly in infants. They may manifest as incompletely developed leaflets, shortened or malformed chordae, small annuli, abnormal size and number of the papillary muscles, or any combination of these defects.
- Infective endocarditis: Large infected vegetations obstructing the orifice of the tricuspid valve may produce stenosis. This condition is relatively uncommon, even in those who abuse intravenous drugs.
- Unusual causes: Rare causes of tricuspid stenosis include Fabry disease and giant blood cysts.
- Mimickers of tricuspid stenosis: Several conditions may mimic tricuspid stenosis by obstructing flow through the valve. These conditions include supravalvular obstruction from congenital diaphragms, intracardiac or extracardiac tumors, thrombosis or emboli, or large endocarditis vegetations. In addition, conditions that impair right-sided filling can produce similar symptoms and physical findings. These conditions include constrictive pericarditis and restrictive cardiomyopathy.
Atrial Myxoma
Cardiomyopathy, Restrictive
Endomyocardial Fibrosis
Infective Endocarditis
Pericarditis, Constrictive
Pericarditis, Constrictive-Effusive
Tricuspid Atresia
Lab Studies
- Complete blood cell count: If the white blood cell count is elevated, infection should be considered. A disproportionately high hemoglobin (polycythemia) level may be indicative of poor pulmonary blood flow.
- Complete chemistry profile: The results of this test may help delineate metabolic abnormalities associated with certain inborn errors of metabolism.
Imaging Studies
- Chest radiography: Cardiac size may range from normal to enlarged (ie, cardiomegaly). Right atrial enlargement may be prominent. Findings specific to a particular associated congenital heart disease may also be seen.
- Echocardiography: This test has become the procedure of choice for the diagnosis of valvular disorders. The test results help delineate the structure of the tricuspid valve and any other intracardiac pathology that may contribute to the pathophysiology of the process.5
Other Tests
Electrocardiogram: Arrhythmias are frequent in this patient population. Because of the enlargement of the right atrium, the presence of atrial flutter and/or fibrillation should not be surprising. In sinus rhythm, right atrial enlargement or abnormality (tall P waves on inferior leads) may be noted.
Procedures
Cardiac catheterization: This may be required prior to surgery in older patients to assess for concomitant coronary artery disease. Right heart catheterization can be used to determine the gradient across the valve and valve area (ie, severity of stenosis) and assess the presence of associated congenital defects (eg, septal defects, intracardiac shunts, anomalous veins) if present. Assessment of aortic and mitral valves via left heart catheterization is useful in patients with rheumatic disease.
Histologic Findings
Most commonly, stenotic tricuspid valves are secondary to rheumatic fever. These generally demonstrate fibrous tissue proliferation without calcium deposits. The leaflet tissue is composed of dense collagen and elastic fibers, producing major distortions of the normal leaflet layers. Congenitally abnormal valves can show a wide spectrum of incompletely developed leaflets, abnormal chordae tendineae, or dysplastic papillary muscles.
Medical Care
In the treatment of tricuspid stenosis, medical care consists of assessment and treatment of the underlying cause of the valvular pathology.
- Treat bacterial endocarditis with the appropriate antibiotics as determined by the sensitivity of the organisms cultured.
- Medically address cardiac arrhythmias depending on their characterization.
- Decreasing right atrial volume overload with diuresis and salt restriction helps decrease symptoms and improve hepatic function.
Surgical Care
Tricuspid stenosis remains a surgical disease and requires either commissurotomy or replacement of the valve if right heart failure or low cardiac output has resulted. Surgery is rarely performed solely on the tricuspid valve; it is usually performed in combination with mitral and/or aortic valve disease repair. (6)
- With tricuspid valve replacement, the risk of thrombosis is significant and many surgeons advise warfarin therapy for either mechanical or bioprosthetic valve placement.
- Percutaneous balloon valvuloplasty has been used successfully, as long as concomitant regurgitation is not significant.
- The therapy chosen depends on the structure of the valve and the degree of deformity encountered.
- When possible, excise intracavitary pathology, whether it be tumors or other structural abnormalities.
- Redundant portions of the dilated right atrium can be excised during the same procedure for restoring the atrium back to normal size.
Consultations
- Consultation with infectious disease specialists may be appropriate if the stenosis is secondary to an infectious process.
- An endocrinologist may be of assistance if carcinoid syndrome or an inborn error of metabolism is the cause of the pathology.
Diet
- No specific dietary restrictions are necessary before therapy.
- Fluid and sodium restriction is prudent if signs of venous congestion are present.
- If a valve replacement is undertaken and the patient must be anticoagulated, dietary instructions must be provided regarding those foods that interfere with anticoagulation and are rich in vitamin K.
Activity
- Activity is usually self-limited by the patient because of easy fatigability secondary to oxygen deprivation.
- Once the pathology has been corrected, no activity restrictions are necessary.
The goals of pharmacotherapy are to reduce morbidity and to prevent complications.
Drug Category: Antiarrhythmic agents
Alter the electrophysiologic mechanisms responsible for arrhythmia.
| Drug Name | Digoxin (Lanoxin) |
|---|
| Description | Cardiac glycoside with direct inotropic effects and indirect effects on the cardiovascular system. Acts directly on cardiac muscle and increases myocardial systolic contractions. Indirect actions result in increased carotid sinus nerve activity and enhanced sympathetic withdrawal for any given increase in mean arterial pressure. |
|---|
| Adult Dose | 0.125-0.375 mg PO qd |
|---|
| Pediatric Dose | Digitalization in infants and children not generally recommended; suggested doses are as follows
TDD:
Premature infants: 0.02-0.03 mg/kg if tablet; 0.015-0.025 mg/kg if capsule, IV, or IM in divided doses
Full-term infants: 0.025-0.035 mg/kg if tablet; 0.02-0.03 mg/kg if capsule, IV, or IM in divided doses
1-24 months: 0.035-0.06 mg/kg if tablet; 0.03-0.05 mg/kg if capsule IV, or IM in divided doses
2-5 years: 0.03-0.04 mg/kg if tablet; 0.025-0.035 mg/kg if capsule, IV, or IM in divided doses
5-10 years: 0.02-0.035 mg/kg if tablet; 0.015-0.030 mg/kg if capsule, IV, or IM in divided doses
>10 years: 0.01-0.015 mg/kg if tablet; 0.008-0.012 mg/kg if capsule, IV, or IM in divided doses
May accomplish digitalization by giving one half TDD in first dose followed by 2 doses that are one fourth TDD given at 8-12h intervals
Maintenance dose:
Premature infants: 0.005-0.0075 mg/kg if tablet; 0.004-0.006 mg/kg if capsule, IV, or IM divided q12h
Full-term infants: 0.006-0.010 mg/kg if tablet; 0.005-0.008 mg/kg if capsule, IV, or IM divided q12h
1-24 months: 0.010-0.015 mg/kg if tablet; 0.0075-0.012 mg/kg if capsule IV, or IM divided q12h
2-5 years: 0.0075-0.010 mg/kg if tablet; 0.006-0.009 mg/kg if capsule, IV, or IM divided q12h
5-10 years: 0.005-0.010 mg/kg if tablet; 0.004-0.008 mg/kg if capsule, IV, or IM divided q12h
>10 years: 0.0025-0.005 mg/kg if tablet; 0.002-0.003 mg/kg if capsule, IV, or IM qd or divided q12h |
|---|
| Contraindications | Documented hypersensitivity; beriberi heart disease; idiopathic hypertrophic subaortic stenosis; constrictive pericarditis; carotid sinus syndrome |
|---|
| Interactions | Medications that may increase levels include alprazolam, benzodiazepines, bepridil, captopril, cyclosporine, propafenone, propantheline, quinidine, diltiazem, aminoglycosides, oral amiodarone, anticholinergics, diphenoxylate, erythromycin, felodipine, flecainide, hydroxychloroquine, itraconazole, nifedipine, omeprazole, quinine, ibuprofen, indomethacin, esmolol, tetracycline, tolbutamide, and verapamil
Medications that may decrease serum levels include aminoglutethimide, antihistamines, cholestyramine, neomycin, penicillamine, aminoglycosides, oral colestipol, hydantoins, hypoglycemic agents, antineoplastic treatment combinations (including carmustine, bleomycin, methotrexate, cytarabine, doxorubicin, cyclophosphamide, vincristine, and procarbazine), aluminum or magnesium antacids, rifampin, sucralfate, sulfasalazine, barbiturates, kaolin/pectin, and aminosalicylic acid |
|---|
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
|---|
| Precautions | Hypokalemia may reduce positive inotropic effect of digitalis; IV calcium may produce arrhythmias in digitalized patients; hypercalcemia predisposes to digitalis toxicity, and hypocalcemia can make digoxin ineffective until serum calcium levels are normal; magnesium replacement therapy must be instituted in patients with hypomagnesemia to prevent digitalis toxicity; patients diagnosed with incomplete AV block may progress to complete block when treated with digoxin; exercise caution in hypothyroidism, hypoxia, and acute myocarditis |
|---|
Drug Category: Anticoagulants
Used for prophylaxis and treatment of venous thrombosis, pulmonary embolism, and thromboembolic disorders.
| Drug Name | Warfarin (Coumadin) |
|---|
| Description | Interferes with hepatic synthesis of vitamin K–dependent coagulation factors. Tailor dose to maintain an INR in the range of 2-3. |
|---|
| Adult Dose | 5-15 mg/d PO for 2-5 d; adjust dose according to desired INR |
|---|
| Pediatric Dose | 0.05-0.34 mg/kg/d PO; adjust dose according to desired INR |
|---|
| Contraindications | Documented hypersensitivity; severe liver or kidney disease; open wounds or GI ulcers |
|---|
| Interactions | Drugs that may decrease anticoagulant effects include griseofulvin, carbamazepine, glutethimide, estrogens, nafcillin, phenytoin, rifampin, barbiturates, cholestyramine, colestipol, vitamin K, spironolactone, oral contraceptives, and sucralfate
Medications that may increase anticoagulant effects include oral antibiotics, phenylbutazone, salicylates, sulfonamides, chloral hydrate, clofibrate, diazoxide, anabolic steroids, ketoconazole, ethacrynic acid, miconazole, nalidixic acid, sulfonylureas, allopurinol, chloramphenicol, cimetidine, disulfiram, metronidazole, phenylbutazone, phenytoin, propoxyphene, sulfonamides, gemfibrozil, acetaminophen, and sulindac |
|---|
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
|
|---|
| Precautions | Do not switch brands after achieving therapeutic response; caution in active tuberculosis or diabetes; patients with protein C or S deficiency are at risk of developing skin necrosis |
|---|
Further Inpatient Care
Inpatient care consists of treating the underlying precipitating condition. For acute bacterial endocarditis or rheumatic causes, antibiotic therapy is indicated until the acute phase has resolved. Then, valve surgery can be considered, if indicated. After valve replacement, inpatient care consists of regulating the anticoagulation and treating postoperative arrhythmias until stability has been achieved. After valve replacement, adjust anticoagulation to an international normalized ratio (INR) of 3-4 because of the low-pressure and low-flow state of the right side. Because of the high risk of thrombosis in this low-pressure system, some authors recommend warfarin therapy for bioprosthetic or mechanical valves.
Further Outpatient Care
Outpatient care consists of routine follow-up care with echocardiography studies to assess valvular function. Check the INR monthly to regulate anticoagulation. In those instances in which the tricuspid stenosis is secondary to some other process (eg, carcinoid, tumor), consider continual surveillance of the underlying disease state.
In/Out Patient Meds
Generally, outpatient medications consist of the anticoagulant warfarin and any antiarrhythmic used to treat atrial fibrillation or flutter, if present. Diuretics may be needed depending on the volume status of the patient.
Deterrence/Prevention
For those cases in which intravenous drug use or bacterial endocarditis was the precipitating event, emphasize careful dental hygiene. Maximize drug detoxification efforts. Of course, do not forget that routine antibiotic coverage should be administered for prevention of endocarditis.
Complications
Complications that can be encountered after tricuspid valve replacement include infection of the prosthetic valve, particularly in those instances when endocarditis was present preoperatively. Tricuspid insufficiency and thromboembolization can also occur.
Prognosis
The prognosis is generally good if therapy is provided for tricuspid stenosis. For those cases in which tumors are the cause of the stenosis, the prognosis is directly related to the prognosis of the underlying disease. In those cases of precipitating infection, if the behavior that caused the initial infection (eg, intravenous drug use) can be modified, prognosis for the patient is good.
Patient Education
Educate patients regarding the adverse effects of anticoagulation. Emphasize instructions regarding dental hygiene and subacute bacterial endocarditis prophylaxis for invasive procedures.
Medical/Legal Pitfalls
The medicolegal pitfalls in this disease process relate to the complications that can occur with surgical intervention. The operative procedure of valve replacement should be explained carefully, as should the potential postoperative sequelae from the intervention and the subsequent medical treatment that may be needed for control of arrhythmias and anticoagulation.
The authors and editors of eMedicine gratefully acknowledge the contributions of previous author Frank M Sheridan, MD to the development and writing of this article.
| Media file 1:
A representation of a stenotic tricuspid valve. This image demonstrates fusion of the commissures (shown as dotted lines). |
 |  View Full Size Image | |
Media type: Image
|
- Lev M, Liberthson RR, Joseph RH, Seten CE, Eckner FA, Kunske RD, et al. The pathologic anatomy of Ebstein's disease. Arch Pathol. Oct 1970;90(4):334-43. [Medline].
- Waller BF. Morphological aspects of valvular heart disease: Part I. Curr Probl Cardiol. Oct 1984;9(7):1-66. [Medline].
- Waller BF. Morphological aspects of valvular heart disease: Part II. Curr Probl Cardiol. Nov 1984;9(8):1-74. [Medline].
- Acikel M, Erol MK, Yekeler I, Ozyazicioglu A. A case of free-floating ball thrombus in right atrium with tricuspid stenosis. Int J Cardiol. Apr 2004;94(2-3):329-30. [Medline].
- Faletra F, La Marchesina U, Bragato R, De Chiara F. Three dimensional transthoracic echocardiography images of tricuspid stenosis. Heart. Apr 2005;91(4):499. [Medline].
- Arnett EN, Roberts WC. Pathology of active infective endocarditis: a necropsy analysis of 192 patients. Thorac Cardiovasc Surg. Dec 1982;30(6):327-35. [Medline].
- Block PC, Bonhoeffer P. Percutaneous approaches to valvular heart disease. Curr Cardiol Rep. Mar 2005;7(2):108-13. [Medline].
- DiSesa VJ, Mills RM Jr, Collins JJ Jr. Surgical management of carcinoid heart disease. Chest. Nov 1985;88(5):789-91. [Medline].
- Kratz JM, Crawford FA Jr, Stroud MR, et al. Trends and results in tricuspid valve surgery. Chest. Dec 1985;88(6):837-40. [Medline].
- Miller BR, Vohr FH, Christian FV, Singh AK. Cardiac valvular replacement in carcinoid heart disease. Am J Med. Nov 1983;75(5):896-8. [Medline].
- Morgan JR, Forker AD, Coates JR, Myers WS. Isolated tricuspid stenosis. Circulation. Oct 1971;44(4):729-32. [Medline].
- Mukhopadhyay S, Suryavanshi S, Yusuf J, et al. Isolated thrombus producing tricuspid stenosis: an unusual presentation in primary antiphospholipid syndrome. Indian Heart J. Jan-Feb 2004;56(1):61-3. [Medline].
- Sakata Y, Koibuchi N, Xiang F, et al. The spectrum of cardiovascular anomalies in CHF1/Hey2 deficient mice reveals roles in endocardial cushion, myocardial and vascular maturation. J Mol Cell Cardiol. Oct 18 2005;[Medline].
- Sharieff S, Saghir T, Shah-e-Zaman K, et al. Concurrent percutaneous valvuloplasty of mitral and tricuspid valve stenoses. J Invasive Cardiol. Jun 2005;17(6):340-2. [Medline].
Tricuspid Stenosis excerpt Article Last Updated: Jul 29, 2008
|
